Patents by Inventor Yanrong DONG

Yanrong DONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PREPARATION SPECIFICALLY BOUND WITH CD137 AND USE THEREOF
    Publication number: 20230285555
    Abstract: Provided by the present application is a preparation, which comprises an antibody specifically bound with CD137 or an antigen-binding fragment thereof, wherein the CD137 antibody comprises a light chain variable region VL and a heavy chain variable region VH, wherein the VL comprises an amino acid sequence shown in any one of SEQ ID NO: 1-11, and the VH comprises an amino acid sequence shown in any one of SEQ ID NO:12-22. Also provided by the present application are a kit comprising the preparation, and a use of the preparation or the kit in the preparation of a drug, the drug being used for the treatment of a cancer.
    Type: Application
    Filed: April 15, 2021
    Publication date: September 14, 2023
    Inventors: Xin ZHANG, Yanrong DONG, Jianjian PENG, Kai FU, Li WANG
  • COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT
    Publication number: 20230118053
    Abstract: The present application provides a medicinal product comprising: an the HER2 inhibitor or a CDK inhibitor, wherein said CDK inhibitor inhibits CDK4 and/or CDK6. The present application also provides an the HER2 inhibitor for the use of treating tumor in combination with a CDK inhibitor, as well as their use in the preparation of a medicament for treating tumor. The combination in present will significantly enhance tumor inhibiting.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 20, 2023
    Inventors: Ting XU, Junfang XU, Pilin WANG, Jing YANG, Jiazhu FANG, Lihong YUN, Yanrong DONG
  • MONOCLONAL ANTIBODY WHICH TARGETS TFPI
    Publication number: 20220325000
    Abstract: Disclosed is a monoclonal antibody or an antigen binding fragment thereof which targets tissue factor pathway inhibitor (TFPI), and a medical use thereof.
    Type: Application
    Filed: August 28, 2020
    Publication date: October 13, 2022
    Applicant: Suzhou Alphamab Co., Ltd.
    Inventors: Ting Xu, Xiaoxiao Wang, Ying Fan, Yanrong Dong, Liping Chen, Jianyun Ji
  • Single domain antibody and derivative proteins thereof against programmed death-ligand (PDL1)
    Patent number: 11225522
    Abstract: The present invention relates to the field of medical biology and discloses a single domain antibody and derivative proteins thereof against programmed death ligand (PDL1). In particular, the present invention discloses a programmed death ligand 1 (PDL1) binding molecule and the use thereof, especially the use for treating and/or preventing or diagnosing PDL1 relevant diseases such as tumor.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: January 18, 2022
    Assignee: Suzhou Alphamab Co., LTD.
    Inventors: Ting Xu, Yanrong Dong, Pilin Wang, Ting Chen
  • SINGLE DOMAIN ANTIBODY AND DERIVATIVE PROTEINS THEREOF AGAINST PROGRAMMED DEATH-LIGAND (PDL1)
    Publication number: 20180327494
    Abstract: The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against programmed death ligand (PDL1). In particular, the present invention discloses a programmed death ligand 1 (PDL1) binding molecular and the use thereof, especially the use for treating and/or preventing or diagnosing PDL1 relevant diseases such as tumor.
    Type: Application
    Filed: August 1, 2016
    Publication date: November 15, 2018
    Inventors: Ting Xu, Yanrong Dong, Pilin Wang, Ting Chen
  • SINGLE DOMAIN ANTIBODY AND DERIVATIVE PROTEINS THEREOF AGAINST PROGRAMMED DEATH-LIGAND (PDL1)
    Publication number: 20180291103
    Abstract: The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against programmed death ligand (PDL1). In particular, the present invention discloses a programmed death ligand 1 (PDL1) binding molecular and the use thereof, especially the use for treating and/or preventing or diagnosing PDL1 relevant diseases such as tumor.
    Type: Application
    Filed: August 1, 2016
    Publication date: October 11, 2018
    Inventors: Ting XU, Yanrong DONG, Pilin WANG, Ting CHEN